Tower Research Capital (TRC)’s Fidelity Disruptive Medicine ETF FMED Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.1K Buy
+65
New +$1.98K ﹤0.01% 5137
2025
Q1
– Sell
-162
Closed -$4K – 5387
2024
Q4
$4K Hold
162
– – ﹤0.01% 4545
2024
Q3
$4.26K Hold
162
– – ﹤0.01% 4621
2024
Q2
$3.9K Hold
162
– – ﹤0.01% 4845
2024
Q1
$4.13K Hold
162
– – ﹤0.01% 4732
2023
Q4
$3.92K Buy
162
+50
+45% +$1.08K ﹤0.01% 5026
2023
Q3
$2.48K Buy
+112
New +$2.68K ﹤0.01% 5143

Other funds holding FMED

Tower Research Capital (TRC)'s FMED Position: Q3 2026 in Review

Tower Research Capital (TRC) opened a new position in Fidelity Disruptive Medicine ETF (FMED) in Q3 2026: 65 shares worth $2.1K. The stake represents ﹤0.01% of the portfolio and ranks #5137 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in FMED as recently as Q4 2024.

Tower Research Capital (TRC) first reported a position in FMED in Q3 2023 and has held it in 7 quarters since. The position peaked at $4.26K in Q3 2024. 14 funds tracked by Wall St. Rank hold FMED as of Q3 2026.

  • Tower Research Capital (TRC) held 65 shares of Fidelity Disruptive Medicine ETF worth $2.1K as of Q3 2026.
  • Fidelity Disruptive Medicine ETF was a new Tower Research Capital (TRC) position in Q3 2026.
  • Fidelity Disruptive Medicine ETF made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q3 2026, its #5137 holding.
  • Tower Research Capital (TRC) first reported a position in Fidelity Disruptive Medicine ETF in Q3 2023 and has held it in 7 quarters since.
  • Tower Research Capital (TRC)'s Fidelity Disruptive Medicine ETF position peaked at $4.26K in Q3 2024.
  • 14 funds tracked by Wall St. Rank held Fidelity Disruptive Medicine ETF as of Q3 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2026, filed 16 Nov 2026.